English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In order to test the effectiveness of adoptive immunotherapy against renal cell carcinoma (RCC) in a mouse model relevant to human disease, we first generated two murine renal cell carcinoma cell lines expressing the human tumor-associated antigen erbB2 by genetic modification of the Renca and SIRCC cell lines. When injected into the kidneys of mice, these cell lines rapidly formed a primary kidney tumor that metastasized to lung, liver and various peritoneal locations. Tumor-specific mouse T cells were generated by genetic modification of splenic T cells in vitro. The transgene encoded a chimeric receptor (T-body) specific for erbB2, in which a single-chain (scFv) anti-erbB2 antibody was linked to T cell activation and costimulatory domains (scFv-erbB2-CD28-zeta), to enable tumor recognition in a major histocompatibility complex-independent manner. Gene-modified T cells expressed the T-body on their surface, and could respond specifically against erbB2-expressing tumor cells as demonstrated by secretion of interferon-gamma. Adoptive transfer of T-body-expressing T cells could lead to inhibition of primary tumor and metastases. Systemic delivery of these gene-modified T cells led to complete eradication of disease in a proportion of mice, and this was associated with peri-vascular tissue inflammation composed of activated lymphoid cells, with macrophages and lesser numbers of eosinophils and neutrophils. This study demonstrated, for the first time, the efficacy of genetically redirected T cells against orthotopic renal cell carcinoma in mice.

Anti-Tumor Activity of Genetically Redirected T Cells Against Orthotopic Kidney Cancer in Mice~!2010-01-06~!2010-03-24~!2010-05-13~!